PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Sean Pokorney, MD, MBA - Episode 1. Looking for Trouble: The Role of Systematic Screening Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 6. Is That Realistic? What We’ve Learned About Anticoagulation Therapy From Real-World Studies Apr 05, 2023

Show notes

Sean Pokorney, MD, MBA - Episode 7. Marching to Their Own Rhythm: Using Consumer Wearables in AF Diagnosis and Treatment Apr 05, 2023

Show notes

Sean Pokorney, MD, MBA - Episode 3. Mending the Healthcare System: Reducing Disparities Apr 05, 2023

Show notes

Aaron T. Gerds, MD, MS / John Mascarenhas, MD - Shaping Modern Management of Myelofibrosis: Guidance on the Conjunction of Targeted Therapy and AlloHCT Apr 04, 2023

Show notes

Go online to PeerView.com/SDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to develop personalized treatment plans for your patients with myelofibrosis (MF) that incorporate the latest therapeutic options, including JAK inhibitors, targeted strategies, and HCT? Find out in this new PeerView CME activity, featuring two experts who will use case-based clinical discussions to illustrate how they manage MF with the individual patient in mind. They will use these cases to discuss eligibility for HCT and the need for pre-HCT therapy based on disease risk factors; use of JAK inhibitor in non-HCT settings; practical dosing and safety management considerations; and the emergence of novel targeted and combinatorial strategies in the MF setting. Watch this informative update on personalized care for patients with MF! Upon completion of this activity, participants should be better able to: Discuss patient- and disease-related features of MF that inform prognosis and guide the selection of JAK inhibitors, other targeted strategies, and HCT; Summarize efficacy and safety data surrounding the use of JAK inhibitors, novel targeted strategies, and innovative combination regimens in MF across the therapeutic continuum; and Develop treatment plans that incorporate JAK inhibitors and other novel therapies to manage MF in HCT and non-HCT settings

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care Mar 29, 2023

Show notes

Go online to PeerView.com/WCP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options. Upon completion of this activity, participants should be better able to: Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis; Identify patients with psoriasis who are most likely to benefit from novel oral treatments; Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines; and Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis.

Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC Mar 28, 2023

Show notes

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes Mar 28, 2023

Show notes

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Mazyar Shadman, MD, MPH, Peter A. Riedell, MD - Finding Treatment Synergy in CLL: Expert Consults on Advances With Targeted and Cellular Therapy Mar 28, 2023

Show notes

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Stephen V. Liu, MD - Perfecting Precision in Modern NSCLC Practice: Are You Optimally Integrating Biomarker-Driven Therapy? Mar 28, 2023

Show notes

Go online to PeerView.com/RYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, extensive and nuanced biomarker testing of complex tumors such as non–small cell lung cancer (NSCLC) is essential to determine the best treatment approach for each patient. Targeted therapies are associated with improved outcomes, and the list of relevant therapeutic targets and matched therapies continues to expand, necessitating more granularity and precision in testing. Which tests are appropriate and how should their results be interpreted to inform clinical decisions? How can biomarker testing information guide optimal treatment selection and sequencing throughout the NSCLC disease continuum, including in earlier disease settings in which adjuvant targeted therapy is now available? These and other key questions are answered in this new educational activity. Experts help you prepare to meet the rising challenges and opportunities that exist with the integration of recently approved and emerging targeted therapies into the modern care of patients with NSCLC. Better grasp the oncogenic role of different genomic alterations and the associated biomarker tests for capturing them to enable the most appropriate selection of targeted therapies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC; Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC; and Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected